Expression pattern of programmed death-1 in lymphocyte-rich classical Hodgkin lymphoma according to the growth patterns

被引:0
|
作者
Go, Jai Hyang [1 ]
机构
[1] Dankook Univ, Dept Pathol, Coll Med, Cheonan, Chungnam, South Korea
关键词
Hodgkin lymphoma; lymphocyte-rich; programmed death-1; T-CELLS; MICROENVIRONMENT; MARKER; PD-1;
D O I
10.4103/0377-4929.191819
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We present a rare case of lymphocyte-rich classical Hodgkin lymphoma ( LRCHL), which exhibited different expression patterns of programmed death-1 ( PD-1) in nodular and interfollicular areas. A 57-year-old male patient presented with neck masses. Neck computed tomography showed enlargement of multiple lymph nodes in right Level II and III. Histologic examination of the excised lymph node revealed LRCHL with nodular and interfollicular patterns. Immunohistochemical analysis for PD-1 revealed a small number of weakly stained cells in the interfollicular area. PD-1 (+) cells were markedly increased in cell number and staining intensity in the nodular area and formed rosettes around the tumor cells.
引用
收藏
页码:538 / 540
页数:3
相关论文
共 50 条
  • [31] Outcomes, Toxicities, and Patterns of Use of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Multicenter Retrospective Study
    Bair, Steven M.
    Strelec, Lauren Elizabeth
    Feldman, Tatyana A.
    Shah, Nirav N.
    Reddy, Nishitha
    Khan, Nadia
    Andreadis, Charalambos
    Ujjani, Chaitra S.
    Singavi, Arun K.
    Howlett, Christina
    Khoan Vu
    Faheem, Malik
    Youngman, Matthew R.
    Nasta, Sunita Dwivedy
    Landsburg, Daniel J.
    Mato, Anthony R.
    Schuster, Stephen J.
    Svoboda, Jakub
    BLOOD, 2017, 130
  • [32] Increased risk of Hodgkin lymphoma in males with inherited T lymphocyte receptor programed death-1 deficiency
    Delamain, Marcia Torresan
    Boas Gomez, Gabriela Vilas
    Lourenco, Gustavo Jacob
    de Souza, Carmino Antonio
    Passos Lima, Carmen Silvia
    LEUKEMIA & LYMPHOMA, 2019, 60 (14) : 3552 - 3556
  • [33] Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's disease
    Diehl, V
    Sextro, M
    Franklin, J
    Hansmann, ML
    Harris, N
    Jaffe, E
    Poppema, S
    Harris, M
    Franssila, K
    van Krieken, J
    Marafioti, T
    Anagnostopoulos, I
    Stein, H
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 776 - 783
  • [34] HIGH EXPRESSION OF PROGRAMMED CELL DEATH RECEPTOR 1 IN THE TUMOR MICROENVIRONMENT IS ASSOCIATED WITH INFERIOR EVENT FREE SURVIVAL IN CLASSICAL HODGKIN LYMPHOMA
    Hollander, P.
    Kamper, P.
    Smedby, K. E.
    Enblad, G.
    Mortensen, J.
    Amini, R. -M.
    d'Amore, F.
    Molin, D.
    Glimelius, I.
    HAEMATOLOGICA, 2016, 101 : 1 - 2
  • [35] Expression of Major Histocompatibility Complex (MHC) Class II, but Not MHC Class I, Predicts Outcome in Patients with Classical Hodgkin Lymphoma (cHL) Treated with Nivolumab (Programmed Death-1 [PD-1] Blockade)
    Roemer, Margaretha G. M.
    Redd, Robert A.
    Cader, Fathima Zumla
    Pak, Christine J.
    Abdelrahman, Sara
    Ouyang, Jing
    Sasse, Stephanie
    Younes, Anas
    Fanale, Michelle A.
    Santoro, Armando
    Zinzani, Pier Luigi
    Timmerman, John M.
    Collins, Graham
    Ramchandren, Rod
    Cohen, Jonathon B.
    De Boer, Jan Paul
    Kuruvilla, John
    Savage, Kerry J.
    Trneny, Marek
    Ansell, Stephen M.
    Sacchi, Mariana
    Farsaci, Benedetto
    Sumbul, Anne
    Armand, Philippe
    Neuberg, Donna S.
    Pinkus, Geraldine S.
    Ligon, Azra H.
    Rodig, Scott J.
    Shipp, Margaret A.
    BLOOD, 2017, 130
  • [36] Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes
    Panjwani, Poonam K.
    Charu, Vivek
    DeLisser, Monique
    Molina-Kirsch, Hernan
    Natkunam, Yasodha
    Zhao, Shuchun
    HUMAN PATHOLOGY, 2018, 71 : 91 - 99
  • [37] Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma
    Lee, Joycelyn J. X.
    Chan, Alexandre
    Tang, Tiffany
    ACTA ONCOLOGICA, 2016, 55 (04) : 519 - 520
  • [38] Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
    Roemer, Margaretha G. M.
    Redd, Robert A.
    Cader, Fathima Zumla
    Pak, Christine J.
    Abdelrahman, Sara
    Ouyang, Jing
    Sasse, Stephanie
    Younes, Anas
    Fanale, Michelle
    Santoro, Armando
    Zinzani, Pier Luigi
    Timmerman, John
    Collins, Graham P.
    Ramchandren, Radhakrishnan
    Cohen, Jonathon B.
    De Boer, Jan Paul
    Kuruvilla, John
    Savage, Kerry J.
    Trneny, Marek
    Ansell, Stephen
    Kato, Kazunobu
    Farsaci, Benedetto
    Sumbul, Anne
    Armand, Philippe
    Neuberg, Donna S.
    Pinkus, Geraldine S.
    Ligon, Azra H.
    Rodig, Scott J.
    Shipp, Margaret A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (10) : 942 - +
  • [39] Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes
    Fan Luo
    Jiaxin Cao
    Feiteng Lu
    Kangmei Zeng
    Wenjuan Ma
    Yan Huang
    Li Zhang
    Hongyun Zhao
    Cancer Cell International, 21
  • [40] Increased programmed death-1+tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival
    Muenst, Simone
    Hoeller, Sylvia
    Dirnhofer, Stephan
    Tzankov, Alexandar
    HUMAN PATHOLOGY, 2009, 40 (12) : 1715 - 1722